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Abstract 
Background: Raised intracranial pressure (ICP) is a prominent cause of morbidity and mortality after severe traumatic 
brain injury (TBI). However, in the clinical setting, little is known about the cerebral physiological response to severe 
and prolonged increases in ICP.
Methods: Thirty-three severe TBI patients from a single center who developed severe refractory intracranial hyper-
tension (ICP > 40 mm Hg for longer than 1 h) with ICP, arterial blood pressure, and brain tissue oxygenation  (PBTO2) 
monitoring (subcohort, n = 9) were selected for retrospective review. Secondary parameters reflecting autoregulation 
(including pressure reactivity index—PRx, which was available in 24 cases), cerebrospinal compensatory reserve (RAP), 
and ICP pulse amplitude were calculated.
Results: PRx deteriorated from 0.06 ± 0.26 a.u. at baseline levels of ICP to 0.57 ± 0.24 a.u. (p < 0.0001) at high levels 
of ICP (> 50 mm Hg). In 4 cases, PRx was impaired (> 0.25 a.u.) before ICP was raised above 25 mm Hg. Concurrently, 
 PBTO2 decreased from 27.3 ± 7.32 mm Hg at baseline ICP to 12.68 ± 7.09 mm Hg at high levels of ICP (p < 0.001). The 
pulse amplitude of the ICP waveform increased with increasing ICP but showed an ‘upper breakpoint’—whereby 
further increases in ICP lead to decreases in pulse amplitude—in 6 out of the 33 patients.
Discussion: Severe intracranial hypertension after TBI leads to decreased brain oxygenation, impaired pressure reac-
tivity, and changes in the pulse amplitude of ICP. Impaired pressure reactivity may denote increased risk of developing 
refractory intracranial hypertension in some patients.
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*Correspondence:  joseph.donnelly@cantab.net 
2 Department of Anaesthesiology, Level 12 Auckland Support Building, 
Auckland City Hospital, University of Auckland, 2 Park Road, Grafton, 
Auckland, New Zealand
Full list of author information is available at the end of the article
Introduction
Raised intracranial pressure (ICP) can occur due to an 
expanding mass lesion or due to increases in volume of 
any of the vascular, cerebrosipinal fluid (CSF) or paren-
chymal compartments within brain [1]. The detrimental 
effects of raised ICP are twofold. One is the develop-
ment of transtentorial pressure gradients that can cause 
focal ischemia of vital brain stem centers leading to 
rapid death. The second is that increased ICP causes an 
increase in cerebral venous pressure by compression 
at the level of the bridging veins, leading in turn to a 
decrease in cerebral perfusion pressure (CPP) and, if CPP 
decreases below the lower limit of autoregulation, global 
cerebral hypoperfusion [2, 3].
Surprisingly, the cerebral physiological sequelae of 
raised ICP secondary to traumatic brain injury (TBI) are 
unclear. As previously shown, increased ICP decreases 
CPP, which with dysfunctional autoregulation, causes a 
decrease in cerebral blood flow, raises arterial blood pres-
sure (ABP), and modifies the ICP pulse waveform [4]. 
However, whether these findings translate to the complex 
situation of raised ICP after severe TBI is uncertain.
In this study, we sought to describe the cerebral oxy-
genation, cerebrovascular pressure reactivity, and ICP 
pulse amplitude response to severe and sustained intrac-
ranial hypertension after severe TBI.
Methods
Study Design and Setting
This study was conducted as a retrospective analysis of a 
prospectively maintained database cohort (1992–2017), 
in which high-frequency physiological monitoring data 
had been archived. Monitoring of brain modalities was 
conducted as a part of standard patient care and archived 
in an anonymized database of physiological monitor-
ing. Data on age, injury severity, and clinical status were 
recorded at the time of monitoring on this database, 
and no attempt was made to re-access clinical records 
for additional information. Since all data were extracted 
from the hospital records and fully anonymized, no data 
on patient identifiers were available, and therefore, for-
mal patient or proxy consent and institutional ethics 
approval were not required.
Participants
TBI patients with a clinical need for ICP monitoring and 
computerized signal recordings were included for analy-
sis. A total of 1146 head-injured patients admitted to the 
Addenbrooke’s Hospital Neurocritical Care Unit between 
1992 and 2017 were included for the initial database. As 
described previously, this is likely to represent approxi-
mately 25% of all TBI admissions and 50% of all TBI 
admissions with ICP monitors [5]. Inclusion criteria were 
as follows: TBI; computerized invasive monitoring of ICP 
and ABP for at least 12 h; admission Glasgow Coma Scale 
(GCS); and 6-month mortality data available. From this 
database of 1146 patients, files were selected that con-
tained an initial ICP less than 25  mm Hg with a subse-
quent ICP rise to over 40 mm Hg for at least an hour. This 
yielded 33 suitable files. Patients were managed accord-
ing to TBI guidelines [6] aimed at keeping ICP < 20 mm 
Hg and CPP > 50–60 mm Hg. While all 33 patients in the 
cohort had computerized ICP monitoring, fewer patients 
had PRx monitoring (n = 24) or brain oxygenation 
monitoring (n = 9). This is because PRx monitoring only 
began in 1996 and brain oxygenation monitoring in 2004.
Data Acquisition and Processing
ICP was monitored with an intraparenchymal sensor 
(Codman ICP MicroSensor, Codman & Shurtleff, Rayn-
ham, Massachusetts). ABP (Baxter Healthcare, Deerfield, 
Illinois) at the level of the right atrium (1992–2015) and 
at the foramen of Monro (2015–2017—one patient). 
Brain tissue oxygenation was monitored using a Licox 
probe via a cranial access device (Technicam, Abbott, 
UK). Probes were positioned at a constant depth in the 
white matter, pericontusional in focal injuries or in the 
non-dominant frontal lobe in diffuse injuries. Probe 
positioning was verified by means of a head computed 
tomography (CT) scan.
All data were sampled at least 50 Hz with proprietary 
data acquisition and analysis software (ICM 1992–2002 
[7] and then with ICM+©, http://www.neuro surg.cam.
ac.uk/icmpl us after 2002). Heart rate was determined 
as the fundamental frequency of the ABP signal over a 
10 s window within the cardiac (40–180 cycles/min) fre-
quency band. Amplitude of the cardiac pulse in ICP and 
ABP was determined as the fundamental amplitude in 
the cardiac frequency band (40–180 cycles/min). ABP 
and ICP signals were averaged (mean) over a 10-s win-
dow; then PRx was calculated as the moving Pearson cor-
relation of 30 consecutive ABP and ICP, updated every 
minute. Cerebrospinal compensatory reserve (RAP) was 
calculated similarly as the moving correlation between 
mean ICP and the pulse amplitude of ICP. AMP was 
divided by aABP (giving AMP/aABP ratio) to get an indi-
cation of the transmission of the cardiac pulse from the 
blood pressure to the ICP.
ICP, ICP pulse amplitude, ABP, ABP pulse amplitude, 
and RAP data were available for all 33 patients, while 
PRx and  PBTO2 were available for 24 and 9 patients, 
respectively.
Statistical Analysis
Data are reported as means and standard deviations. 
The relationship between minute-by-minute values 
of mean ICP and ICP pulse amplitude was fitted with 
a generalized additive model allowing for three differ-
ent segments (cubic regression spline smooth). The 
number of segments (3) was chosen a priori to allow 
for 3 different portions of the ICP, AMP relationship 
(~ flat at low ICP, steep rising segment, and an upper 
breakpoint).
For the aggregate relationship between ICP or CPP and 
intracranial parameters (PRx, RAP, AMP), the means 
of each variable from each patient were calculated in 
10 mm Hg wide intervals of ICP and CPP and then local 
regression smoothing (LOWESS) was applied. This bin-
ning procedure, prior to LOWESS fitting was to ensure 
that patients with longer recordings did not contrib-
ute disproportionately to parts of the smooth. Pairwise 
comparisons between physiological variables at the dif-
ferent ICP levels were performed using Student’s t test. 
No adjustments for multiple comparisons were made in 
this exploratory analysis. To test whether early PRx was 
different between those who developed refractory high 
ICP and TBI patients who did not, we first identified con-
trols for the 24 cases who had simultaneous ICP and PRx 
data with 24 controls (selected from the 1146 patients) 
who were matched for sex, initial GCS and age. Then we 
performed a Wilcox test for the ICP values between the 
two groups. Because the primary aim of this study was 
descriptive, we used all available cases in the database 
rather than performing a priori sample size calculations. 
We used the R language and software environment for 
statistical computation (R Core Team 2015 version 2.12.1 
[8]) using the following packages: dplyr [9], ggplot2 [10], 
gam [11], and MatchIt [12]. The significance level was set 
at 0.05.
Results
Admission characteristics are displayed in Table 1. Of the 
33 patients, 7 were female and the mean age was 30.3. 
In the cohort, ICP rose from a mean minimum of 5.46 
(± 6.1) to a mean maximum of 74.67(± 22.76). Seventeen 
of the patients died.
Two patient examples illustrating the heterogene-
ous nature of the response to intracranial hypertension 
are depicted in Fig.  1. In the patient in Fig.  1a, PRx is 
initially preserved and only becomes impaired after 
the development of raised ICP. In the other patient 
(Fig.  1b), PRx is clearly disturbed prior to the devel-
opment of severe refractory raised ICP. In this case, a 
decrease in  PBTO2 followed the decrease in CPP almost 
linearly to reach oxygen pressures of less than 5 mm Hg. 
In addition, a dissociation between the rise in mean ICP 
and pulse amplitude of ICP can be seen near the end 
of the recording, such that with increasing ICP, pulse 
amplitude remained constant. This failure for ICP pulse 
amplitude to increase despite increases in mean ICP has 
been postulated to be due to critical cerebrovascular 
collapse.
Across all patients, PRx (Fig.  2) showed a general 
increasing trend, signifying disturbed autoregulation 
with increasing ICP and of note, the PRx at baseline 
levels of ICP is disturbed in a number of the patients 
(‘Appendix’ Fig.  7). As expected, PRx plotted against 
CPP reveals a steadily increasing PRx with decreas-
ing CPP. The relationship between mean ICP (and 
CPP) levels and ICP pulse amplitude is depicted in 
Figs.  3 and 4. In general, ICP amplitude increased 
monotonically with increasing mean ICP (12 patients; 
Fig. 3c); however, in 6 of the cases an upper breakpoint 
(a switch from a positive to a negative relationship 
between mean ICP and ICP pulse amplitude) is seen at 
high ICPs (Fig.  3a). In 13 patients, a rightward deflec-
tion of the AMP–ICP was detected (Fig.  3b). In the 
remaining 2 patients, AMP monotonically decreased 
with increasing ICP (up until ICP 40  mm Hg—not 
included in figure). Similar responses were seen when 
ICP pulse amplitude was normalized to the arterial 
pulse amplitude (Fig.  4, middle panel). The index of 
cerebral compensatory reserve, RAP, increased from 
low to moderate levels of ICP and thereafter showed a 
gradual decline with further increases in ICP (Fig. 4e). 
At all levels of ICP or CPP, the averaged RAP response 
was greater than + 0.3 a.u.
When all 9 available  PBTO2 responses are viewed 
together (Fig.  5),  PBTO2 shows a steady decrease with 
increasing ICP. However, the between patients response 
is strikingly variable (Fig. 8 ‘Appendix’). When  PBTO2 is 
plotted against CPP, a consistent pattern is seen, with a 
relatively preserved  PBTO2 with mild decreases in CPP 
followed by a steeper decrease with moderate to severe 
decreases in CPP. All but one patient shows a decrease 
in  PBTO2 with decreasing CPP.
When compared to 24 controls (severe TBI patients, 
matched for age, sex, and initial GCS), initial mean PRx 
in the first five hours of monitoring was higher (Fig. 6) 
in the cases of refractory intracranial hypertension. 
Table 1 Patient demographics; cerebral effects of  refrac-
tory intracranial hypertension after TBI
CPP cerebral perfusion pressure, GCS Glasgow coma scale, ICP intracranial 
pressure, PRx pressure reactivity index
Overall
N 33
Age (years) (mean (sd)) 30.30 (12.54)
Sex = male (number, %) 26 (78.8)
GCS <= 8 (number, %) 28 (84.8)
Monitoring length (h) (mean (sd)) 188.53 (145.40)
Decompressive craniectomy (number, %)
 No 15 (45.5)
 Yes 11 (33.3)
 NA 7 (21.2)
ICP (mm Hg) (mean (sd)) 25.60 (8.71)
Max ICP (mm Hg) (mean (sd)) 74.67 (22.76)
Min ICP (mm Hg) (mean (sd)) 5.46 (6.10)
CPP (mm Hg) (mean (sd)) 67.70 (10.98)
PRx (a.u.) (mean (sd); n = 24) 0.16 (0.25)
Mortality = dead (%) 17 (51.5)
While ICP was also higher, this did not reach statistical 
significance (Wilcox p = 0.197).
Grouping each of the patients’ data into three ICP 
groups (< 25, 25–50, > 50  mm Hg; Table  2) confirmed 
the visual interpretation of Figs. 2, 3, and 4).
Discussion
By isolating the rare cases of severe refractory intrac-
ranial hypertension with multimodality monitoring, we 
describe the cerebral physiological response to raised 
ICP after TBI. Although only exploratory, these data 
highlight the impact of raised ICP on cerebral autoreg-
ulation, the sensitivity of brain tissue oxygenation to 
raised ICP and the possible role of impaired pressure 
reactivity in identifying at-risk patients.
Autoregulation Parameters
Raised ICP impairs dynamic cerebral autoregulation 
(Fig.  2, Table  2). This confirms previous investigations 
of autoregulation during short-term increases in ICP 
(plateau waves) [13, 14] and is consistent with a recent 
large between patient analysis that found a significant 
Fig. 1 Neuromonitoring during severe intracranial hypertension in two traumatic brain-injured patients. On the left, ICP rises to 70 mm Hg over a 
period of 12 h and PRx was not significantly impaired prior to the increase in mean ICP. In addition, although  PBTO2 decreased with increasing ICP, it 
did not reach severely hypoxic values even during the maximal mean ICP  (PBTO2 ~ 20 mm Hg at ICP 60 mm Hg). On the right, ICP rises dramatically 
from below 20 mm Hg to over 60 mm Hg in the space of 10 h. This increase in ICP was associated with a fall in CPP, and brain tissue oxygenation. 
In this case, PRx was disturbed (> 0.25) even in the first 3 h, while ICP was under 20 mm Hg. Despite large increases in ICP over the last 5 h, pulse 
amplitude of ICP (yellow) shows little change. These two cases illustrate that refractory intracranial hypertension may have different neuromonitor-
ing phenotypes. ICP intracranial pressure; AMP pulse amplitude of ICP; MAP mean arterial pressure; CPP cerebral perfusion pressure;  PBTO2 brain 
tissue oxygenation; PRx pressure reactivity index; RAP index of cerebrospinal compensatory reserve
correlation between mean ICP over the whole moni-
toring period and mean PRx [15]. In contrast to these 
studies, however, the current analysis observed changes 
within patients and over periods of time that are substan-
tially longer than the calculation window for PRx. There-
fore, the finding of impaired PRx with increasing ICP is 
unlikely to be explained by between patient confounding 
factors or time-resolution limitations of the PRx method. 
Similarly, PRx deteriorates with decreased CPP, rep-
resenting the lower half of the ‘U-shaped’ relationship 
between CPP and PRx [16].
Perhaps most striking though, is that PRx was dis-
turbed before the onset of intracranial hyperten-
sion in a selection of the patients. This has been 
observed previously in a cohort of brain-injured 
patients of mixed pathologies (subarachnoid hemor-
rhage, hypoxic brain injury, trauma), but has not been 
statistically assessed [17]. After matching cases of 
severe refractory high ICP for age, initial GCS, and 
sex, we found that PRx in the first 5 h was higher in 
those who developed raised ICP. The same was not 
true for the mean ICP over the first 5  h, although 
this did approach statistical significance (p = 0.197). 
This highlights the potential utility of continuous 
assessments of cerebral autoregulation in predicting 
raised ICP events. Encouragingly, a previous investi-
gation found that a feature similar to PRx (the long 
term mean arterial pressure (MAP)-ICP correlation 
from low-frequency data) can help predict periods 
of raised ICP 30 min before they occur [18]. Identify-
ing patients at risk of raised ICP may prove crucial 
as raised ICP carries a high risk of mortality, and 
perhaps the most effective ICP treatments, such as 
decompression, require some time to mobilize.
Reasons why impaired cerebral pressure reactiv-
ity may be a harbinger of raised ICP in some patients 
but not others deserves further discussion as it per-
haps reflects different pathophysiological profiles of 
intracranial hypertension. Intracranial hypertension is 
a result of changes in compartmental volumes within 
the brain: increases in volume of the brain tissue (for 
example cerebral edema), the cerebral spinal fluid, or 
the blood (venous or arterial). Disturbed autoregula-
tion preceding an increase in ICP may indicate a pri-
mary vascular dysfunction that, over time, causes 
raised ICP. In these cases, a vascular dysfunction as 
manifest in impaired PRx could lead to vasogenic 
edema, which over hours could lead to progressive 
increases in ICP. Cases where ICP and PRx are dis-
turbed simultaneously indicate that either the impaired 
vascular function is a consequence of the raised ICP, 
or the underlying pathophysiological mechanism is 
occurring rapidly. Simultaneous perturbations in PRx 
and ICP could conceivably occur with obstruction in 
CSF flow, a rapidly expanding lesion or during a sud-
den increase in blood volume.
Fig. 2 PRx response to refractory intracranial hypertension expressed relative to changes in ICP (left) and CPP (right) (LOWESS with 95% confidence 
interval; n = 24). Pressure reactivity increased with increasing ICP and PRx plotted against CPP revealed a partial ‘U-shaped’ curve as previously 
described. PRx is well maintained until CPP drops below 70 mm Hg, below which PRx deteriorates. PRx pressure reactivity; ICP intracranial pressure; 
CPP cerebral perfusion pressure
In addition, we found a consistent increase in MAP at 
elevated levels of ICP (Table 1. While previous experi-
mental work has shown profound Cushing vasopressor 
responses to extreme and rapid increases in ICP [2, 19], 
in these data we cannot rule out a confounding effect of 
concurrent interventions and medications such as cool-
ing or vasopressors.
Brain Oxygenation
In this sample of patients with extreme increases in 
ICP,  PBTO2 overall decreased. This is consistent with a 
recent experimental study which demonstrated a corti-
cal vulnerability to increased ICP [4]. However, there was 
marked variation between patients in the levels of  PBTO2 
and the response to increased ICP. This highlights the 
complex nature of the  PBTO2 variable. It does not merely 
index brain perfusion, but the complicated interplay 
between cerebral oxygen delivery (dependent on  PaO2, 
Hb, CBF), metabolic rate of the nearby cerebral tissues, 
and any diffusion barriers [20–22]. Therefore, many clini-
cal scenarios, potentially independent of perfusion, may 
affect brain oxygenation such as red blood cell transfu-
sion, hypoxia or hyperoxia, mitochondrial dysfunction 
[23–25]. The position of the oxygen sensing probe may 
also be relevant as intracontusional oxygen monitoring 
should be different to pericontusional or healthy tissue 
monitoring [26]. Furthermore, the depth of probe may 
also be relevant; in basilar artery dependent rabbits with 
CSF infusion induced increases in ICP, the cortical laser 
Doppler flux was more sensitive to increases in ICP than 
the global basilar artery flow velocity [4].
Nevertheless, monitoring of brain oxygenation, some-
times in combination with cerebral microdialysis has 
increased in popularity over last decade with some prom-
ising initial results. In a retrospective analysis compar-
ing before  PBTO2 to after  PBTO2-targeted therapy, found 
that keeping  PBTO2 above 20  mm Hg was associated 
with decreased mortality [27]. In addition, similar to 
PRx, brain tissue monitoring has been combined with 
ABP and CPP monitoring to yield continuous autoregu-
lation assessment in TBI and subarachnoid hemorrhage 
[28–30].
The Mean ICP and ICP Pulsatile Amplitude Relationship
The increase in pulsatility of ICP with increasing levels 
of mean ICP has been interpreted as a loss of cerebral 
compensatory reserve. In this scenario, when the intrac-
ranial system is on the steep ascending portion of the 
pressure–volume curve, a pulsatile injection of blood 
volume from the cardiac cycle would be expected to 
produce a large increase in pulsatile pressure. However, 
at extreme levels of ICP (approaching diastolic blood 
pressure) it has been demonstrated in animal models 
that ICP pulsations may in fact decrease [31]. This has 
been proposed to be related to critical closing of the 
Fig. 3 The ICP amplitude—mean ICP relationship (n = 33). Three 
distinct patterns were identified; those with an upper breakpoint (A, 
n = 6), a rightward deflected pattern (B, n = 13) or those with a mono-
tonic increasing pattern (C, n = 12). In 2 patients, AMP decreased 
with increasing ICP (not shown). ICP intracranial pressure; AMP pulse 
amplitude of ICP
cerebrovascular bed [7]. Observing this phenomenon 
is, however, far from universal in refractory intracranial 
hypertension (Fig. 3), probably as its occurrence is mul-
tifactorial, depending on parameters such as vasomotor 
tone, cerebral intravascular pressures and arterial blood 
pulse pressure. Interestingly, RAP—the short-term cor-
relation between changes in mean ICP and mean ampli-
tude of ICP—did not show a similar upper breakpoint 
like the pulsatility–mean ICP relationship and rarely 
reached negative values (Fig. 4 and 1) as may have been 
expected at these extreme levels of ICP [32]. This per-
haps reflects the short-term dynamic nature of the RAP 
calculation (calculated over a 5-min time window) com-
pared with the extended time windows associated with 
the pulsatility-mean ICP relationship.
Limitations
Due to the small sample size, these analyses must be con-
sidered as preliminary descriptions. While it was pos-
sible to include more patients by relaxing the definition 
Fig. 4 Relationship between ICP (left) or CPP (right) with ICP amplitude, transmission of arterial to intracranial pulse, and RAP (LOWESS with 95% 
confidence interval; n = 33). When all patients are grouped together, an upper breakpoint in the AMP–ICP relationship occurs at around 70 mm Hg. 
A similar response is seen for arterial to intracranial pulse transmission indicating that a decreased ABP amplitude is not responsible for the AMP-ICP 
upper breakpoint. RAP increases from low (0 mm Hg) to moderate ICP (~ 30 mm Hg) and thereafter decreases with further increase in ICP. ICP intrac-
ranial pressure; CPP cerebral perfusion pressure; RAP cerebrospinal compensatory reserve
of refractory intracranial hypertension, we wished to 
describe the physiological response across the wid-
est range of ICPs and therefore opted to only include 
patients with severe intracranial hypertension. Further, 
because intracranial physiology will depend heavily on 
concurrent therapies, detailed clinical annotations to the 
monitoring data would aid interpretation and increase 
the generalizability of the study. Stratification of physi-
ological responses to intracranial hypertension by ICP 
treatment modality (for example decompression or bar-
biturates) may yield useful information describing early 
indicators of a beneficial versus a pathological physi-
ological response. The association between early PRx and 
later development of intracranial hypertension needs to 
be treated with caution as the case–control analysis was 
only carried out in a small subset of patients with con-
current PRx monitoring (n = 24). Furthermore, time 
points besides the first 5 h for the ability of PRx to pre-
dict intracranial hypertension should be investigated. In 
addition, the current study does not address the prag-
matic issue of how multimodality monitoring data can be 
integrated into clinical care without causing a detrimen-
tal information overload. While ongoing data collection 
with the increasing availability of multimodality monitor-
ing will likely shed light on this area in the near future, 
controlled experimental studies that mimic the increase 
Fig. 5 PBTO2 response to refractory intracranial hypertension expressed relative to changes in ICP (left) and CPP (right) (LOWESS with 95% confidence inter-
val; n = 9). When expressed against ICP,  PBTO2 demonstrates a steady decrease. When expressed in relation to changes in CPP, the relationship resembles the 
autoregulation curve; with moderate levels of CPP (70- > 90 mm Hg), oxygenation is well maintained, but lower than 70 mm Hg, oxygenation decreases (by 
approximately 0.5 mm Hg per 1 mm Hg decrease in CPP.  PBTO2 brain tissue oxygenation; ICP intracranial pressure; CPP cerebral perfusion pressure
Fig. 6 PRx over the first 5 h in patients who went on to develop 
severe refractory intracranial hypertension (n = 24) compared to 
severe TBI patients matched for age, sex and initial GCS (n = 24). 
Those who developed severe refractory intracranial hypertension 
tended to have higher PRx in the first 5 h of monitoring (p = 0.048) 
while ICP was not significantly different between the two groups 
(p = 0.197). PRx pressure reactivity index; ICP intracranial pressure
in ICP observed after human TBI need to also play a role 
as they can effectively isolate the effects of the disease 
from that of treatment.
Conclusion
Severe intracranial hypertension after TBI leads to 
decreased brain oxygenation, impaired pressure reac-
tivity, and a characteristic ICP pulsatility response.
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Table 2 Physiologic response to high intracranial pressure after TBI (mean (sd); n = 33 unless stated otherwise)
ICP intracranial pressure, AMP pulse amplitude of ICP, aABP amplitude of arterial blood pressure, MAP mean arterial pressure, CPP cerebral perfusion pressure, HR heart 
rate, PRx pressure reactivity index, RAP cerebrospinal compensatory reserve, PBTO2 brain tissue oxygenation
Variable 0–25 mm Hg 25–50 mm Hg 50–150 mm Hg p (elevated vs. 
base)
p (severe vs. 
elevated)
ICP (mm Hg) 17.52 (3.85) 32.80 (2.39) 61.04 (10.79) < 0.001 < 0.001
AMP (mm Hg) 1.83 (1.36) 3.10 (2.08) 5.34 (4.26) 0.02 < 0.001
AMP/aABP (a.u.) 0.10 (0.06) 0.17 (0.10) 0.29 (0.22) 0.02 < 0.001
CPP (mm Hg) 73.90 (9.27) 63.79 (10.41) 39.27 (18.11) < 0.001 < 0.001
MAP (mm Hg) 91.42 (9.87) 96.61 (9.48) 99.82 (12.55) 0.01 0.120
aABP (mm Hg) 18.87 (3.32) 19.70 (4.21) 19.85 (5.85) 0.16 0.712
HR (bpm) 77.53 (15.35) 79.46 (19.04) 83.78 (20.72) 0.50 0.214
PRx (a.u.)
(n = 24)
0.06 (0.26) 0.21 (0.30) 0.57 (0.24) 0.01 < 0.001
RAP (a.u.) 0.54 (0.20) 0.59 (0.25) 0.46 (0.27) 0.29 0.005
PBTO2 (mm Hg) (n = 9) 27.27 (7.32) 20.78 (5.43) 12.68 (7.09) 0.06 0.02
Appendix
See Figs. 7 and 8. 
Fig. 7 Individual PRx responses to refractory intracranial hypertension expressed relative to changes in ICP (left) and CPP (right) (n = 24). While pres-
sure reactivity index increased with increasing ICP in each patient, in some patients, PRx was disturbed (above > 0.25) even at relatively normal ICP 
(below 25 mm Hg). PRx plotted against CPP revealed a partial ‘U-shaped’ curve in most patients, as previously described. PRx is well maintained until 
CPP drops below 70 mm Hg, below which PRx deteriorates. PRx pressure reactivity; ICP intracranial pressure; CPP cerebral perfusion pressure
Fig. 8 Individual  PBTO2 response to refractory intracranial hypertension expressed relative to changes in ICP (left) and CPP (right) (n = 9). Brain tissue 
oxygenation response to increases in ICP showed marked variability between patients with some patients showing relatively preserved  PBTO2 with 
increasing ICP, some showing precipitous hypoxia, and some showing a paradoxical increase in oxygenation. A similar variability is observed with 
respect to CPP. This variability highlights the complex nature of the  PBTO2 signal; it is contributed to by respiratory  (FiO2,  PaO2), hematological (Hb), 
cardiovascular (cardiac output, cerebral blood flow) and metabolic factors (brain metabolism)
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